No Data
Zhejiang Medicine (600216.SH): The planned production of vitamins E by the company is not fixed.
Zhejiang Medicine (600216.SH) stated on the investor interaction platform on July 25 that the planned production of the company's vitamins E is not fixed. The company adjusts its production plan based on production conditions, market demand and other factors. Please refer to the "Analysis Table of Production and Sales Volume" in the company's annual report for the actual production volume of the company's products.
Zhejiang Medicine Co., Ltd. (SHSE:600216) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Zhejiang Medicine (600216.SH): The life nutrition sector includes vitamin D3.
Zhejiang Medicine (600216.SH) stated on the investor interaction platform on July 19 that its life nutrition sector includes vitamin D3, but the product's production and sales volume accounts for an insignificant proportion of the company's overall revenue and the overall market demand for the product. Therefore, the company expects that changes in the market quote for this product will not have a significant impact on its performance.
Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Stock Is Going Strong: Have Financials A Role To Play?
Zhejiang Medicine (600216.SH) will distribute equity for the year 2023: 0.15 yuan per share.
Zhejiang Medicine (600216.SH) announced the implementation of equity distribution for the year 2023: before the implementation of the plan...
Individual Investors in Zhejiang Medicine Co., Ltd. (SHSE:600216) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 5.9% Last Week
The Three-year Shareholder Returns and Company Earnings Persist Lower as Zhejiang Medicine (SHSE:600216) Stock Falls a Further 4.0% in Past WeekNo Data
